ClinicalTrials.gov
ClinicalTrials.gov Menu

Reproducibility of RNFL and ONH Measurements in OAG With Heidelberg Spectralis SD-OCT Glaucoma Module Premium Edition

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02247284
Recruitment Status : Recruiting
First Posted : September 25, 2014
Last Update Posted : June 20, 2017
Sponsor:
Information provided by (Responsible Party):
University of Zurich

Brief Summary:
The purpose of this study is to assess and compare the repeatability of SD-OCT (Spectralis™ OCT, Version 6.0, Heidelberg Engineering, Germany) RNFL thickness measurements with a new software (glaucoma premium module) with the well established peripapillary RNFL thickness measurements in patients with primary open angle glaucoma.

Condition or disease Intervention/treatment Phase
Primary Open Angle Glaucoma Device: RNFL and BMO-MRW SD-OCT Not Applicable

Detailed Description:

The purpose of this study is to assess and compare the repeatability of SD-OCT (Spectralis™ OCT, Version 6.0, Heidelberg Engineering, Germany) RNFL thickness measurements with the new software (method B) and with the previous method of measurement (method A) in patients with glaucoma.

It is a prospective, not blinded, not randomised, monocentric study. Inclusion of 50 patients with a diagnosis of primary open angle glaucoma (POAG), that will be recruited from the ophthalmology outpatient department of the UniversityHospital Zurich, Switzerland. All patients will undergo a full ophthalmic examination including measurement of refraction, best corrected visual acuity, examination of anterior and posterior compartment and measurement of the intraocular pressure. On the same day they will have 3 OCT examinations with a new method of measurement (method B).On the same day the first 10 patients will undergo also 3 OCT examinations with the previous method (method A) and they will get an other 3 OCT examinations with method B by a second observer. For this 10 patients the next consultation (3 months +/- 1 month) the 3 OCT examinations with method B will be repeated by the first observer.

Primary objectives are coefficient of variations (COV) of method A and B; Intra-class-correlations (ICC) of method A and B.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Study to Investigate Reproducibility of the New Heidelberg Spectralis SD-OCT Glaucoma Module Premium Edition (Software Version 6.0) in Comparison to Reproducibility of RNFL Scans.
Study Start Date : March 2015
Estimated Primary Completion Date : December 2017
Estimated Study Completion Date : December 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Glaucoma

Arm Intervention/treatment
Experimental: group 1
patient with a diagnosis of primary open angle glaucoma will undergo 'RNFL and BMO-MRW SD-OCT' measurements with Heidelberg Spectralis SD-OCT old protocoll and Glaucoma Premium Module (new) protocoll, which in addition to RNFL measurements include measurement of Bruch's Membrane Opening-based minimum rim width (BMO-MRW).
Device: RNFL and BMO-MRW SD-OCT
Masurement of peripapillary RNFL measurements with Heidelberg Spectralis SD-OCT (Heidelberg Engeneering GmbH, Heidelberg, Germany) old protocoll and in addition with the new Glaucoma Premium Module (software version 6.0) tocoll, which in addition to RNFL measurements include measurement of Bruch's Membrane Opening-based minimum rim width (BMO-MRW).




Primary Outcome Measures :
  1. Retinal nerve fiber layer thickness (RNFL) [ Time Frame: baseline and 3 months +/- 1 month ]
    Retinal nerve fiber layer thickness (RNFL) measured with Spectralis OCT

  2. Bruch's membrane opening-based minimum rim width (BMO-MRW) [ Time Frame: baseline and 3 months +/- 1 month ]
    Bruch's membrane opening-based minimum rim width (BMO-MRW) measured with Spectralis OCT


Secondary Outcome Measures :
  1. Coefficient of variations (COV) of RNFL and BMO-MRW [ Time Frame: baseline and 3 months +/- 1 month ]
    Coefficient of variations (COV) of RNFL and BMO-MRW

  2. Intra-class-correlations (ICC) of RNFL and BMO-MRW [ Time Frame: baseline and 3 months +/- 1 month ]
    Intra-class-correlations (ICC) of RNFL and BMO-MRW



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • diagnosis of POAG glaucoma
  • male and female patients aged 18 years or older, no upper limit
  • written informed consent
  • visual acuity of more or equal to 0.5 Snellen
  • refractive error between + /- 6.00 D spheric and under or equal than 2.00 D cylindrical

Exclusion Criteria:

  • history of surgery other than uncomplicated cataract surgery
  • disease affecting cornea, anterior compartment, lens, vitreous body
  • history of severe ocular disease, particularly diseases affecting the optic nerve, other than glaucoma
  • history of ocular trauma

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02247284


Contacts
Contact: Jens Funk, MD, PhD +41 255 1111

Locations
Switzerland
UniversityHospital Zurich Recruiting
Zurich, ZH, Switzerland, 8091
Contact: Jens Funk, MD, PhD    +41 44 255 1111      
Sub-Investigator: Marc Toeteberg-Harms, MD, FEBO         
Sponsors and Collaborators
University of Zurich
Investigators
Principal Investigator: Jens Funk, MD, PhD UniversityHospital Zurich, Zurich, Switzerland

Responsible Party: University of Zurich
ClinicalTrials.gov Identifier: NCT02247284     History of Changes
Other Study ID Numbers: Glaucoma-Premium-OCT
First Posted: September 25, 2014    Key Record Dates
Last Update Posted: June 20, 2017
Last Verified: June 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Glaucoma
Glaucoma, Open-Angle
Ocular Hypertension
Eye Diseases